Related Experiment Video
Updated: Jun 14, 2025
06:50
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
2.5K
Anti-TCP1 Antibody Is a Potential Biomarker for Diagnosing Systemic Lupus Erythematosus
Sang-Won Lee1, Wook-Young Baek1, So-Won Park1
1Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
International Journal of Molecular Sciences
|August 29, 2024
Summary
Researchers identified anti-chaperonin-containing t-complex polypeptide-1 (TCP1) antibodies as a potential biomarker for systemic lupus erythematosus (SLE). Elevated levels were found in SLE patients compared to healthy individuals and those with other autoimmune diseases.
Area of Science:
- Immunology
- Autoimmune Diseases
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibodies.
- Identifying specific biomarkers is crucial for accurate SLE diagnosis and management.
Purpose of the Study:
- To identify novel autoantibodies as potential biomarkers for SLE.
- To validate the diagnostic potential of the anti-chaperonin-containing t-complex polypeptide-1 (TCP1) antibody in SLE.
Main Methods:
- Protein chip analysis was used to screen for SLE-specific autoantibodies.
- Dot blot and enzyme-linked immunosorbent assays (ELISAs) were employed to validate antibody specificity and quantify levels.
Main Results:
- Protein chip analysis revealed 63 SLE-specific autoantibodies, with anti-TCP1 showing higher expression in SLE patients.
- Dot blot confirmed anti-TCP1 antibodies in 79% of SLE patients, with significantly higher levels than in healthy controls and patients with rheumatoid arthritis, Behçet's disease, or systemic sclerosis.
- ELISA further demonstrated markedly elevated anti-TCP1 antibody levels in SLE patients (50.1 AU) compared to healthy controls (33.9 AU) and other autoimmune disease cohorts.
Conclusions:
- The anti-TCP1 antibody is a promising diagnostic biomarker for SLE.
- Elevated anti-TCP1 antibody levels show high specificity for SLE, distinguishing it from other autoimmune conditions.
